For much of modern cancer medicine, treatment has meant bringing something from outside the body: a drug, a radiation beam, an antibody or a transplant. CAR T-cell therapy follows a different logic. It begins with the patient’s own immune cells, gives them new instructions in a laboratory, and returns them to the bloodstream as a living treatment.
The approach is not a universal cure, and it is not simple to deliver. It can cause serious, sometimes life-threatening side effects, and some cancers eventually return. Yet for patients with certain advanced blood cancers—especially when standard treatments have stopped working—CAR T-cell therapy has produced deep and lasting remissions. It represents one of medicine’s clearest examples of biology being redesigned for an individual patient.
Turning immune cells into targeted hunters
The key cell is the T lymphocyte, an immune cell that can identify and destroy abnormal or infected cells. Cancer, however, often finds ways to hide from T cells or suppress their activity. CAR T-cell therapy attempts to give those T cells a more direct way to find their target.
Scientists add a synthetic structure called a chimeric antigen receptor, or CAR, to the surface of the T cell. The receptor is engineered to recognize a particular molecule on cancer cells. Once the modified T cell binds to that target, internal signals activate the cell, encouraging it to multiply and attack.
The receptor is not a naturally occurring part of the patient’s immune system. It is assembled from several biological components, including an outside-facing recognition section and internal signaling sections that help the T cell respond. That combination allows the treatment to borrow an immune cell’s natural killing ability while giving it a new address.
A treatment made for one person at a time
CAR T-cell treatment is a process rather than a single injection. First, clinicians collect white blood cells from the patient through a procedure called leukapheresis. Blood passes through a machine that separates out selected cells and returns the remaining components to the patient. For related reading, see TIL Therapy: How a Patient’s Own Immune Cells Are Opening a New Front Against Solid Tumors.
The T cells are then sent to a specialized manufacturing facility. There, technicians activate the cells and introduce genetic instructions for the CAR, commonly using a modified viral vector. The cells are expanded until there are enough for treatment, then tested, frozen or transported according to the product’s manufacturing requirements.
Before the cells are infused, the patient usually receives a short course of chemotherapy known as lymphodepletion. This conditioning treatment reduces some existing immune cells and helps create space for the engineered cells to expand. The CAR T cells are then given back through an intravenous infusion.
Afterward, clinicians watch closely. The cells may continue multiplying inside the body, which is part of what makes the therapy powerful—and part of what makes its effects difficult to predict. A patient’s response depends on the cancer, the target chosen, the condition of the immune system and the behavior of the manufactured cells.
From experimental idea to approved treatment
The concept grew out of decades of immunology research. Scientists had long understood that T cells could kill abnormal cells, but they needed a reliable way to direct them toward cancer. Researchers eventually combined antibody-like recognition with T-cell signaling, creating receptors that could recognize targets on the cell surface.
Clinical trials in leukemia and lymphoma showed why the approach attracted so much attention. Some patients whose disease had resisted several previous treatments experienced complete remission after receiving CAR T cells. In a complete remission, tests find no detectable evidence of the cancer, although doctors still monitor patients because remission does not guarantee that the disease can never return.
In 2017, the U.S. Food and Drug Administration approved the first CAR T-cell therapies. One was for certain children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Another was for some adults with advanced large B-cell lymphomas. Since then, the FDA has approved additional products and expanded the use of CAR T-cell therapy to other B-cell cancers and multiple myeloma.
These approvals changed the role of the immune system in cancer care. T cells were no longer only something doctors hoped would help indirectly. They could be collected, modified, multiplied and administered as a regulated cellular medicine. For related reading, see CAR-T Therapy Is Moving Beyond Cancer—and Toward a New Immune-System Reset.
Why the treatment can be dangerous
The same immune activation that can attack cancer can also affect the rest of the body. One of the most familiar complications is cytokine release syndrome, often called CRS. As CAR T cells and other immune cells become activated, they can release signaling proteins called cytokines. The result may include fever, low blood pressure, rapid heartbeat, breathing problems and effects on other organs.
Another complication is immune effector cell-associated neurotoxicity syndrome, or ICANS. It can cause confusion, difficulty speaking, sleepiness, seizures or other changes in brain function. Medical teams trained to recognize these reactions can provide close monitoring and treatments that reduce inflammation or control symptoms.
Patients may also face infections, low blood-cell counts and a weakened immune response, particularly when treatment affects normal B cells as well as malignant ones. In 2024, the FDA required boxed warnings about the risk of T-cell malignancies for certain approved autologous CAR T-cell products after reports of secondary cancers. The agency continued to describe the overall benefit-risk assessment as favorable for their approved uses, while emphasizing the need for long-term monitoring.
These risks help explain why CAR T-cell therapy is offered through specialized centers. Treatment requires more than a cell laboratory. It calls for physicians, nurses, pharmacists and hospital teams who can manage rapid immune reactions and support patients through a demanding recovery.
The limits of a remarkable success
CAR T-cell therapy works best when cancer cells display a clear target that the engineered receptor can recognize. Many blood cancers meet that requirement. Solid tumors are more difficult. Their targets may also appear on healthy tissues, their internal environment can suppress immune cells, and cancer cells can lose or alter the target that CAR T cells are designed to find.
Manufacturing is another challenge. Because most approved CAR T-cell products are made from the patient’s own cells, preparation can take time. A patient’s illness may progress while the cells are being produced. The process is also expensive and depends on specialized facilities, transportation and quality controls. For related reading, see The Whole-Eye Transplant: How Surgeons Made a Human Eye Part of a Living Patient.
Researchers are testing ways to make the therapy faster, safer and more broadly available. One direction involves “off-the-shelf” cells made from a donor or from stem-cell-derived sources. Another involves CARs that recognize more than one cancer marker, potentially making it harder for a tumor to escape by losing a single target. Scientists are also studying ways to improve the cells’ persistence and function inside solid tumors.
Beyond cancer?
The success of CAR T cells has encouraged researchers to ask whether engineered immune cells could be used against diseases other than cancer. Early studies are exploring the possibility of targeting harmful immune cells in severe autoimmune disorders. The idea is still investigational for these uses and should not be confused with an FDA-approved standard treatment.
That research reflects a broader change in medicine. Cells are no longer viewed only as passive material collected from the body. Under the right conditions, they can become programmable tools—capable of sensing a molecular feature, receiving an internal instruction and carrying out a biological task.
A new model for personalized medicine
CAR T-cell therapy does not replace surgery, chemotherapy, radiation or other forms of cancer treatment. Its importance is more specific: it has shown that a patient’s immune system can be collected and rebuilt into a treatment designed around the biology of that person’s disease.
For some patients with otherwise difficult-to-treat blood cancers, that redesign has meant a remission measured not in weeks, but in years. For researchers, it has opened a platform for asking more ambitious questions about what living medicines can do.
The next phase will depend on solving practical and biological problems at the same time: reaching more patients, reducing dangerous side effects, lowering manufacturing barriers and making engineered cells work against cancers that remain out of reach. The field’s central achievement is already clear. Medicine has learned how to take one of the body’s own defenders, give it a new target and return it to the fight.
Use: Regulatory background, approved uses, safety information and FDA warnings for CAR T-cell products.
Use: Explanation of how CAR T-cell therapy is made and used, its development and its risks.
Use: Definition and clinical description of ICANS, a neurological complication associated with immune-cell therapies.
Use: Definition and explanation of cytokine release syndrome following immune-based treatments.
